Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The morphological growth patterns of colorectal liver metastases are prognostic for overall survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Mother-child transmission of epigenetic information by tunable polymorphic imprinting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Epidemiology of chronic red-cell transfusion recipients in Sweden and Denmark-a 10 year follow-up study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Allelic loss at chromosome 9q31-34 is a frequent event in many lymphoproliferative malignancies. Here, we examined DBC1 at 9q33.1 as a potential target in lymphomagenesis. DBC1 is a putative tumor suppressor that has been shown to be involved in the regulation of cell growth and programmed cell death. The methylation status of the DBC1 promoter CpG island was examined by methylation-specific PCR, bisulfite sequencing, and methylation-specific melting curve analysis. DBC1 was hypermethylated in 5 of 5 B-cell-derived lymphoma cell lines, 41 of 42 diffuse large B-cell lymphomas, 24 of 24 follicular lymphomas, 5 of 5 mantle cell lymphomas, 4 of 4 small lymphocytic lymphomas, 1 of 2 lymphoplasmacytoid lymphomas, and in 12 of 12 acute lymphoblastic leukemias, but was unmethylated in 1 case of splenic marginal zone lymphoma, in 12 of 12 multiple myelomas, in 24 of 24 reactive lymph nodes, and in 12 of 12 samples of blood lymphocytes from random donors. DBC1 hypermethylation was associated with transcriptional silencing in lymphoma cell lines, and reexpression of this gene could be induced by treatment with the demethylating agent, 5-aza-2'-deoxycytidine. Our data suggest that hypermethylation of the DBC1 promoter region is a frequent event during the development of lymphoproliferative malignancies, and that DBC1 hypermethylation may serve as a marker for these cancers.

OriginalsprogEngelsk
TidsskriftModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Vol/bind21
Udgave nummer5
Sider (fra-til)632-8
Antal sider7
ISSN0893-3952
DOI
StatusUdgivet - maj 2008

ID: 45731836